Anne Marie Queenan
Research Subjects
Anne Marie Queenan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Karen Bush
The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869,1 and The Mount Sinai Hospital, New York, New York 100292
2 shared publicationsAntone A. Medeiros
<!--label omitted: 6-->Miriam Hospital, Brown University, Providence, Rhode Island 029066
1 shared publicationCarlos Torres-Viera
<!--label omitted: 2-->Beth Israel Deaconess Medical Center2 and
1 shared publicationGeorge M. Eliopoulos
<!--label omitted: 2-->Beth Israel Deaconess Medical Center2 and
1 shared publicationHoward S. Gold
<!--label omitted: 2-->Beth Israel Deaconess Medical Center2 and
1 shared publicationJanet Hindler
<!--label omitted: 5-->University of California at Los Angeles Medical Center, Los Angeles, California 900245; and
1 shared publication
Latest Publications
- Open Access
- 1 November 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (11) , 3189-3194
Cloning and Biochemical Characterization of FOX-5, an AmpC-Type Plasmid-Encoded β-Lactamase from a New York City Klebsiella pneumoniae Clinical Isolate
Klebsiella pneumoniae 5064, isolated in New York, carried plasmid-mediated resistance to multiple β-lactams and was unresponsive to clavulanic acid. The β-lactamase gene responsible for cephalosporin resistance encoded FOX-5, with 96 to 97% amino acid identities to other members of the FOX family of β-lactamases. The bla FOX-5 coding region was located next to a transposase gene from the Aeromonas salmonicida insertion element IS AS2 .
- 1 November 2001
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (11) , 3189-3194
Open AccessCloning and Biochemical Characterization of FOX-5, an AmpC-Type Plasmid-Encoded β-Lactamase from a New York City Klebsiella pneumoniae Clinical Isolate
Klebsiella pneumoniae 5064, isolated in New York, carried plasmid-mediated resistance to multiple β-lactams and was unresponsive to clavulanic acid. The β-lactamase gene responsible for cephalosporin resistance encoded FOX-5, with 96 to 97% amino acid identities to other members of the FOX family of β-lactamases. The bla FOX-5 coding region was located next to a transposase gene from the Aeromonas salmonicida insertion element IS AS2 .
- 1 November 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (11) , 3035-3039
SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens Strains
Three sets of carbapenem-resistant Serratia marcescens isolates have been identified in the United States: 1 isolate in Minnesota in 1985 (before approval of carbapenems for clinical use), 5 isolates in Los Angeles (University of California at Los Angeles [UCLA]) in 1992, and 19 isolates in Boston from 1994 to 1999. All isolates tested produced two β-lactamases, an AmpC-type enzyme with pI values of 8.6 to 9.0 and one with a pI value of approximately 9.5. The enzyme with the higher pI in each strain hydrolyzed carbapenems and was not inhibited by EDTA, similar to the chromosomal class A SME-1 β-lactamase isolated from the 1982 London strain S. marcescens S6. The genes encoding the carbapenem-hydrolyzing enzymes were cloned in Escherichia coli and sequenced. The enzyme from the Minnesota isolate had an amino acid sequence identical to that of SME-1. The isolates from Boston and UCLA produced SME-2, an enzyme with a single amino acid change relative to SME-1, a substitution from valine to glutamine at position 207. Purified SME enzymes from the U.S. isolates had β-lactam hydrolysis profiles similar to that of the London SME-1 enzyme. Pulsed-field gel electrophoresis analysis revealed that the isolates showed some similarity but differed by at least three genetic events. In conclusion, a family of rare class A carbapenem-hydrolyzing β-lactamases first described in London has now been identified in S. marcescens isolates across the United States.
- 1 November 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (11) , 3035-3039
SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens Strains
Three sets of carbapenem-resistant Serratia marcescens isolates have been identified in the United States: 1 isolate in Minnesota in 1985 (before approval of carbapenems for clinical use), 5 isolates in Los Angeles (University of California at Los Angeles [UCLA]) in 1992, and 19 isolates in Boston from 1994 to 1999. All isolates tested produced two β-lactamases, an AmpC-type enzyme with pI values of 8.6 to 9.0 and one with a pI value of approximately 9.5. The enzyme with the higher pI in each strain hydrolyzed carbapenems and was not inhibited by EDTA, similar to the chromosomal class A SME-1 β-lactamase isolated from the 1982 London strain S. marcescens S6. The genes encoding the carbapenem-hydrolyzing enzymes were cloned in Escherichia coli and sequenced. The enzyme from the Minnesota isolate had an amino acid sequence identical to that of SME-1. The isolates from Boston and UCLA produced SME-2, an enzyme with a single amino acid change relative to SME-1, a substitution from valine to glutamine at position 207. Purified SME enzymes from the U.S. isolates had β-lactam hydrolysis profiles similar to that of the London SME-1 enzyme. Pulsed-field gel electrophoresis analysis revealed that the isolates showed some similarity but differed by at least three genetic events. In conclusion, a family of rare class A carbapenem-hydrolyzing β-lactamases first described in London has now been identified in S. marcescens isolates across the United States.